☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ELARA Study
Novartis Presents Results of Kymriah in P-II ELARA Study for Relapsed or Refractory Follicular Lymphoma at ASCO 2021
June 3, 2021
Novartis Reports Results of Kymriah (tisagenlecleucel) in P-II ELARA Study for Follicular Lymphoma
August 4, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.